<PAPER><mode2 name='PMC4176467' hasDoc='yes' version='597'></mode2><article xmlns:mml='http://www.w3.org/1998/Math/MathML' xmlns:xlink='http://www.w3.org/1999/xlink' article-type='research-article'><front><journal-meta><journal-id journal-id-type='nlm-ta'>Dement Geriatr Cogn Dis Extra</journal-id><journal-id journal-id-type='iso-abbrev'>Dement Geriatr Cogn Dis Extra</journal-id><journal-id journal-id-type='publisher-id'>DEE</journal-id><journal-title-group><journal-title>Dementia and Geriatric Cognitive Disorders EXTRA</journal-title></journal-title-group><issn pub-type='ppub'>1664-5464</issn><issn pub-type='epub'>1664-5464</issn><publisher><publisher-name>S. Karger AG</publisher-name><publisher-loc>Allschwilerstrasse 10, P.O. Box · Postfach · Case postale, CH–4009, Basel, Switzerland · Schweiz · Suisse, Phone: +41 61 306 11 11, Fax: +41 61 306 12 34, karger@karger.ch</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type='pmcid'>4176467</article-id><article-id pub-id-type='doi'>10.1159/000363500</article-id><article-id pub-id-type='publisher-id'>dee-0004-0335</article-id><article-categories><subj-group subj-group-type='heading'><subject>Original Research Article</subject></subj-group></article-categories><title-group><article-title><s sid='1'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1>Agitation in Dementia: Relation to Core Cerebrospinal Fluid Biomarker Levels</s></article-title></title-group><contrib-group><contrib contrib-type='author'><name><surname>Bloniecki</surname><given-names>Victor</given-names></name><xref rid='aff1' ref-type='aff'>a</xref></contrib><contrib contrib-type='author'><name><surname>Aarsland</surname><given-names>Dag</given-names></name><xref rid='aff2' ref-type='aff'>b</xref><xref rid='aff3' ref-type='aff'>c</xref></contrib><contrib contrib-type='author'><name><surname>Cummings</surname><given-names>Jeffrey</given-names></name><xref rid='aff5' ref-type='aff'>e</xref></contrib><contrib contrib-type='author'><name><surname>Blennow</surname><given-names>Kaj</given-names></name><xref rid='aff3' ref-type='aff'>c</xref></contrib><contrib contrib-type='author'><name><surname>Freund-Levi</surname><given-names>Yvonne</given-names></name><xref rid='aff1' ref-type='aff'>a</xref><xref rid='cor1' ref-type='corresp'>*</xref></contrib></contrib-group><aff id='aff1'><sup>a</sup>Division of Clinical Geriatrics, Karolinska University Hospital Huddinge, Stockholm, Mölndal, Sweden</aff><aff id='aff2'><sup>b</sup>Center for Alzheimer Research, Division for Neurogeriatrics, Department of Neurobiology, Caring Sciences and Society (NVS), Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Mölndal, Sweden</aff><aff id='aff3'><sup>c</sup>Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska University Hospital, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden</aff><aff id='aff4'><sup>c</sup>Center for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway, USA</aff><aff id='aff5'><sup>e</sup>Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nev., USA</aff><author-notes><corresp id='cor1'>*Yvonne Freund-Levi, Division of Clinical Geriatrics, Department of Neurobiology, Caring Sciences and Society (NVS), Karolinska Institutet, Karolinska University Hospital Huddinge, SE-146 86 Stockholm (Sweden), E-Mail <email>Yvonne.Freund-Levi@ki.se</email></corresp><fn fn-type='other'><p>V.B. and Y.F.-L. share the first authorship. Trial registration: Karolinska University Hospital identifier study ID: 20100039.</p></fn></author-notes><pub-date pub-type='collection'><season>May-Aug</season><year>2014</year></pub-date><pub-date pub-type='epub'><day>27</day><month>8</month><year>2014</year></pub-date><pub-date pub-type='pmc-release'><day>27</day><month>8</month><year>2014</year></pub-date><volume>4</volume><issue>2</issue><fpage>335</fpage><lpage>343</lpage><permissions><copyright-statement>Copyright © 2014 by S. Karger AG, Basel</copyright-statement><copyright-year>2014</copyright-year><license license-type='open-access' xlink:href='http://creativecommons.org/licenses/by-nc/3.0/'><license-p>This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions.</license-p></license></permissions><abstract><sec><title>Background</title><p><s sid='2'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1>The objective of this study was to examine the associations of agitation with the cerebrospinal fluid dementia biomarkers total-tau (T-tau), phosphorylated-tau (P-tau) and Aβ<sub>1-42</sub>.</s></p></sec><sec><title>Methods</title><p><s sid='3'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1>One hundred patients (mean age ± SD, 78.6 ± 7.5 years) with dementia and neuropsychiatric symptoms, of whom 67% were female, were included.</s><s sid='4'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Agitation was measured using the Cohen-Mansfield Agitation Inventory (CMAI; 46.5 ± 11.8 points).</s></p></sec><sec><title>Results</title><p><s sid='5'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1>Total CMAI correlated with T-tau [r<sub>s</sub> (31) = 0.36, p = 0.04] and P-tau [r<sub>s</sub> (31) = 0.35, p = 0.05] in patients with Alzheimer's disease (AD; n = 33) but not in the total dementia population (n = 95).</s></p></sec><sec><title>Conclusions</title><p><s sid='6'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>Our results suggest that tau-mediated pathology including neurofibrillary tangles and the intensity of the disease process might be associated with agitation in AD.</s></p></sec></abstract><kwd-group><title>Key Words</title><kwd>Dementia</kwd><kwd>Agitation</kwd><kwd>CMAI</kwd><kwd>Cerebrospinal fluid (CSF)</kwd><kwd>Dementia biomarkers</kwd><kwd>Neurofibrillary tangles</kwd><kwd>Behavioral and psychological symptoms in dementia (BPSD)</kwd></kwd-group><counts><fig-count count='1'></fig-count><table-count count='2'></table-count><ref-count count='34'></ref-count><page-count count='9'></page-count></counts></article-meta></front><body><sec id='sec1_1'><title>Background</title><p><s sid='7'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>The global prevalence of dementia is increasing and it is predicted to affect over 80 million individuals worldwide by the year of 2040 [<xref rid='B1' ref-type='bibr'>1</xref>].</s><s sid='8'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The dementia syndrome includes a progressive deterioration of cognitive functions often accompanied by neuropsychiatric symptoms referred to as behavioral and psychological symptoms in dementia (BPSD) [<xref rid='B2' ref-type='bibr'>2</xref>,<xref rid='B3' ref-type='bibr'>3</xref>].</s></p><p><s sid='9'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>BPSD can be divided into three main clusters: agitation, psychosis and mood disorders [<xref rid='B4' ref-type='bibr'>4</xref>].</s><s sid='10'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Agitation includes both emotional distress and behavioral changes such as aggression, irritability, pacing and restlessness [<xref rid='B4' ref-type='bibr'>4</xref>].</s><s sid='11'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Agitation is experienced by approximately 20% of the dementia patients in a community setting and increases up to 50% in institutionalized patients [<xref rid='B5' ref-type='bibr'>5</xref>].</s><s sid='12'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Overall, more than 90% of the patients with dementia suffer from at least one BPSD symptom during the course of the disease [<xref rid='B6' ref-type='bibr'>6</xref>].</s><s sid='13'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> BPSD are major contributors to increased disease burden for both patients and caregivers, reduce the ability to perform activities of daily living, contribute to earlier hospitalization and constitute approximately 30% of the dementia-associated treatment costs [<xref rid='B7' ref-type='bibr'>7</xref>,<xref rid='B8' ref-type='bibr'>8</xref>,<xref rid='B9' ref-type='bibr'>9</xref>,<xref rid='B10' ref-type='bibr'>10</xref>].</s></p><p><s sid='14'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Overall, the research regarding the pathology of BPSD has been limited.</s><s sid='15'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Animal models using male transgenic APP/PS1 mice resulting in rapid progression of amyloid neuropathology have been shown to exhibit behavioral symptoms including disinhibition such as impulsivity, reduced body weight and enhanced aggression relative to wild-type controls [<xref rid='B11' ref-type='bibr'>11</xref>].</s><s sid='16'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Agitation has also been associated with the presence of neurofibrillary tangles (NFT).</s><s sid='17'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In a postmortem study of patients with severe Alzheimer's disease (AD), increased cerebral burden of NFTs in the orbitofrontal cortex was found to correlate with agitation [measured by the Neuropsychiatric Inventory (NPI) agitation subscale] [<xref rid='B12' ref-type='bibr'>12</xref>].</s><s sid='18'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In a study from 2002, an aggressive behavior cluster including actions such as physical aggression, aggressive resistance and verbal aggression was associated with loss of neurons in the rostral locus coeruleus [<xref rid='B13' ref-type='bibr'>13</xref>].</s><s sid='19'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Furthermore, it is very possible that abnormalities in cerebral neurotransmission are involved in the cause of BPSD [<xref rid='B14' ref-type='bibr'>14</xref>].</s></p><p><s sid='20'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Recent studies have shown that the cerebrospinal fluid (CSF) biomarkers total- tau (T-tau), phosphorylated-tau (P-tau) and the 42 amino acid isoform of β-amyloid protein (Aβ<sub>1-42</sub>) can identify AD with high specificity and sensitivity [<xref rid='B15' ref-type='bibr'>15</xref>,<xref rid='B16' ref-type='bibr'>16</xref>,<xref rid='B17' ref-type='bibr'>17</xref>].</s><s sid='21'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Much data suggest that the CSF level of T-tau reflects the intensity of the neuronal degeneration, while P-tau levels correlate with cortical NFT load [for review, see [<xref rid='B15' ref-type='bibr'>15</xref>]].</s><s sid='22'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> In contrast, less is known about the relationship between these biomarkers and BPSD.</s><s sid='23'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In a recent study, apathy was shown to correlate with increased levels of both P-tau and T-tau in CSF, suggesting that apathy could be associated with increased amounts of NFTs in the brain [<xref rid='B18' ref-type='bibr'>18</xref>].</s><s sid='24'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The association between depression and AD biomarkers has also been studied, but no evidence that links depression with the presence of amyloid plaques or NFTs was found [<xref rid='B18' ref-type='bibr'>18</xref>,<xref rid='B19' ref-type='bibr'>19</xref>].</s><s sid='25'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Levels of CSF Aβ<sub>1-42</sub> have been shown to display a negative correlation with increased aggressive behavior in demented patients [<xref rid='B20' ref-type='bibr'>20</xref>].</s><s sid='26'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Several studies indicate that NFTs and amyloid plaques could be involved in the pathological process causing BPSD but this has not been proven and further research is warranted [<xref rid='B11' ref-type='bibr'>11</xref>,<xref rid='B12' ref-type='bibr'>12</xref>,<xref rid='B18' ref-type='bibr'>18</xref>,<xref rid='B19' ref-type='bibr'>19</xref>,<xref rid='B20' ref-type='bibr'>20</xref>].</s><s sid='27'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Current pharmacological treatment options for agitation mainly include antipsychotics, which display modest efficacy and might be associated with severe cerebrovascular events [<xref rid='B21' ref-type='bibr'>21</xref>,<xref rid='B22' ref-type='bibr'>22</xref>].</s><s sid='28'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> This accentuates the importance of identifying potential targets for novel drug development.</s></p><p><s sid='29'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1>The primary aim of this study was to examine the association between agitation as measured by the Cohen-Mansfield Agitation Inventory (CMAI) and the CSF biomarkers T-tau, P-tau and A<sub>β1-42</sub> in patients with dementia and BPSD.</s></p></sec><sec sec-type='materials|methods' id='sec1_2'><title>Materials and Methods</title><sec id='sec2_1'><title>Patients</title><p><s sid='30'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1>One hundred and forty-five patients living in the community were referred from general practitioners to the Memory Clinic of the Department of Geriatric Medicine at Karolinska University between January 2003 and September 2005.</s><s sid='31'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> One hundred patients who fulfilled the criteria according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) [<xref rid='B23' ref-type='bibr'>23</xref>] for the diagnosis of Alzheimer's dementia with behavioral disturbance, vascular dementia with behavioral disturbance and mixed dementia with behavioral disturbance were included in the study.</s><s sid='32'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> A total score of at least 10 on the NPI [<xref rid='B24' ref-type='bibr'>24</xref>] with symptoms for at least 2 weeks prior to inclusion was required.</s><s sid='33'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Patients were excluded if they had a diagnosis of schizophrenia or other psychiatric disorders according to the DSM-IV, a history of seizures, active peptic ulcer or clinically significant hepatic, renal, pulmonary or metabolic disturbances.</s><s sid='34'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> None of the patients were receiving any kind of dementia medication such as cholinesterase inhibitors or neuroleptics prior to inclusion, although some patients were medicated with psychotropics (n = 48) including antidepressants, benzodiazepines and antihistamines at the time of study entry.</s><s sid='35'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The included patient data is part of a larger study that is currently in preparation, but for further information regarding the study population, assessment and other study specifics, please see the original article [<xref rid='B25' ref-type='bibr'>25</xref>].</s></p></sec><sec id='sec2_2'><title>Clinical Assessment</title><p><s sid='36'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>Diagnostic procedures included somatic, psychiatric, neurological and neuroimaging (CT scans) examination performed by a licensed specialist in geriatric medicine with experience in dementia (Y.F.-L.).</s><s sid='37'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> In addition to a clinical interview of patients and caregivers, a standardized scale of cognition [Mini-Mental State Examination (MMSE)] [<xref rid='B26' ref-type='bibr'>26</xref>] and neuropsychiatric symptoms (NPI) was administered for diagnostic purposes.</s><s sid='38'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Lumbar punctures were performed and CSF was collected according to the standard operation procedures for dementia investigation existing in Sweden, in which lumbar punctures are a part of the clinical approach to dementia diagnosis.</s><s sid='39'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Lumbar puncture was successfully performed in 95 of the 100 included patients (3 patients refused the procedure, 1 patient had an arachnoid cyst and in 1 patient, LP was unsuccessful due to muscular rigidity.)</s></p><p><s sid='40'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>The level of agitation was assessed using the CMAI [<xref rid='B27' ref-type='bibr'>27</xref>], which consists of 29 subitems related to agitation that are measured and rated based on frequency 1-7 (1 = never, 7 = a couple of times every hour).</s><s sid='41'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The total CMAI is calculated as the sum of the frequency scores with a maximum score of 203.</s><s sid='42'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The CMAI can be separated into four subitems relating to different subtypes of agitation: subitem 1 = aggressive physical behavior such as kicking or hitting, subitem 2 = nonaggressive physical behavior such as pacing, subitem 3 = verbal aggressive behavior such as screaming and subitem 4 = verbal nonaggressive behavior including negativism or complaining.</s></p><p><s sid='43'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1>Of the 95 patients who underwent a successful lumbar puncture, 35% were diagnosed with AD, 27% had mixed AD with vascular factors, 18% had vascular dementia, 12% were diagnosed with mild cognitive impairment and 8% were diagnosed with unspecified dementia.</s><s sid='44'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> Sixty-three (66%) were females, the mean age was 78.6 years (SD ± 7.5) and the mean total CMAI score was 46.3 (SD ± 11.8).</s></p></sec><sec id='sec2_3'><title>CSF Analyses</title><p><s sid='45'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1>CSF (6 ml) was collected and then stored in polypropylene tubes.</s><s sid='46'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The first 2 ml of every sampling was discarded and the rest was centrifuged at 3,000 rpm for 10 min at +4°C and frozen in aliquots of 2 ml at −70°C.</s><s sid='47'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The collected CSF was used for analysis of T-tau, P-tau and Aβ<sub>1-42</sub> at the Department of Clinical Neurochemistry, Mölndal Hospital.</s><s sid='48'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The T-tau concentration in CSF was determined using a sandwich ELISA (INNOTEST® hTAU Ag; Innogenetics, Gent, Belgium) specifically constructed to measure all tau isoforms irrespectively of phosphorylation status [<xref rid='B28' ref-type='bibr'>28</xref>].</s><s sid='49'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Tau phosphorylated at threonine 181 (P-tau181) was measured using a sandwich ELISA method [INNOTEST® PHOSPHO-TAU (181P); Innogenetics] [<xref rid='B29' ref-type='bibr'>29</xref>].</s><s sid='50'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Aβ<sub>1-42</sub> levels were determined using a sandwich ELISA method [INNOTEST® β-AMYLOID (1-42); Innogenetics] specifically constructed to measure Aβ containing both the first and the 42nd amino acid [<xref rid='B30' ref-type='bibr'>30</xref>].</s><s sid='51'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> In this assay, the monoclonal antibody 21F12, which is highly specific to the C-terminus of Aβ<sub>1-42</sub>, was used for capture, and 3D6, which is specific to the N-terminus, was used as detector.</s></p></sec><sec id='sec2_4'><title>Statistics</title><p><s sid='52'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>Since the investigated variables are scores from ordinal scales, it can be argued that nonparametrical methods are better suited than parametrical ones.</s><s sid='53'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> For associations between the included variables, Spearman's rank order correlation was used.</s><s sid='54'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> To adjust for potential confounders, all significant results were adjusted for age, gender and the level of cognitive impairment (MMSE) using linear regression, and all results where validated for normality, linearity and equal variance.</s><s sid='55'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The sample size was relatively small so that nonparametric regression could not be used since it requires larger sample sizes than regression based on parametric methods.</s><s sid='56'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Data are given as means and 95% confidence intervals (CI) or as stated, and p values &lt;0.05 were considered statistically significant.</s><s sid='57'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> All statistical analyses were carried out with the Statistica® 10.0 software package (StatSoft, Tulsa, Okla., USA).</s></p></sec><sec id='sec2_5'><title>Ethics</title><p><s sid='58'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Informed consent was obtained from the subjects or their legally acceptable representative prior to inclusion.</s><s sid='59'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The regional Ethics Committee of Karolinska Institute, Stockholm, Sweden, approved the study (registration number 441/01 at Karolinska Institutet).</s></p></sec></sec><sec sec-type='results' id='sec1_3'><title>Results</title><p><s sid='60'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>Characteristics of the cohort are shown in table <xref rid='T1' ref-type='table'>1</xref>.</s></p><sec id='sec2_6'><title>Relation between Agitation and AD Biomarkers in CSF</title><p><s sid='61'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>No statistically significant correlations were found between total CMAI, CMAI subscores and the CSF biomarkers T-tau, P-tau and Aβ<sub>1-42</sub> when analyzing all included patients (n = 95).</s><s sid='62'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Within the AD group (n = 33) both T-tau [r<sub>s</sub> (31) = 0.36, p = 0.04] and P-tau [r<sub>s</sub> (31) = 0.35, p = 0.05] (Spearman's rank correlation) were significantly correlated with total CMAI (fig. <xref rid='F1' ref-type='fig'>1</xref>).</s><s sid='63'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> AD patients also displayed a significant correlation between T-tau and CMAI subitem nonaggressive physical behavior [r<sub>s</sub> (31) = 0.4, p = 0.02].</s><s sid='64'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> There were no significant associations between the levels of Aβ<sub>1-42</sub> and agitation (total CMAI) [r<sub>s</sub> (31) = −0.11, p = 0.6] in the AD patients.</s><s sid='65'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> No other significant correlations were found in the AD group.</s><s sid='66'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> No significant correlations were found between any of the dementia biomarkers and total CMAI in the other dementia subgroups (data not shown).</s><s sid='67'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Correlation analyses are shown in table <xref rid='T2' ref-type='table'>2</xref>.</s></p><p><s sid='68'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1>Linear regression analysis confirmed the correlations between agitation and the AD biomarkers in the AD subgroup.</s><s sid='69'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> When adjusted for age, gender and MMSE score, T-tau displayed a significant correlation with total CMAI [F(1,28) 4.45, p = 0.04].</s><s sid='70'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The analysis showed that a one-unit increase of T-tau results in a 0.008-unit increase in total CMAI.</s><s sid='71'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The association between P-tau and total CMAI remained significant after adjustment for all aforementioned variables [F(1,28) 7.16, p = 0.01].</s><s sid='72'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> A one-unit increase of P-tau was associated with a 0.11-unit increase in the total CMAI score.</s><s sid='73'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The correlation between T-tau and nonaggressive physical behavior remained significant after adjustment for confounders, and a one-unit increase of P-tau was associated with a 0.05-unit increase in the CMAI subitem score.</s></p></sec></sec><sec sec-type='discussion' id='sec1_4'><title>Discussion</title><p><s sid='74'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>This is one of the first studies analyzing levels of CSF AD biomarkers in patients with significant neuropsychiatric symptoms and dementia.</s><s sid='75'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> The main finding was a significant relationship between agitation and CSF levels of both T-tau and P-tau in patients with AD.</s><s sid='76'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Based on our previous research [<xref rid='B31' ref-type='bibr'>31</xref>], these results suggest that the cerebral NFT burden is associated with agitation in dementia.</s><s sid='77'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> These findings are also consistent with previous research showing a correlation between agitation and NFT burden in AD patients post mortem [<xref rid='B12' ref-type='bibr'>12</xref>].</s><s sid='78'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> T-tau was also correlated with agitation, suggesting that agitation is associated with the amount of axonal degeneration and the intensity of the disease process [<xref rid='B31' ref-type='bibr'>31</xref>].</s><s sid='79'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Furthermore, our results are supported by the fact that they remained significant even after performing multivariable linear regression to adjust for the effect of dementia severity as measured by MMSE, since it is known that the dementia severity is associated with agitation.</s><s sid='80'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> The tau-mediated pathology is unlikely to be a direct cause of agitation in AD but rather a part of a complicated network of different pathological mechanisms.</s><s sid='81'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> The neuronal damage caused by the NFTs could affect neurotransmission resulting in agitation, as has previously been proposed [<xref rid='B14' ref-type='bibr'>14</xref>], and a study including both neurotransmitters and biomarkers would facilitate further investigation of these associations.</s><s sid='82'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Previous research has indicated that frontal lobe circuit dysfunction, possibly involving tau-mediated pathology, could be a cause of agitation in dementia [<xref rid='B32' ref-type='bibr'>32</xref>].</s><s sid='83'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Although our results are significant, a previous study comparing agitation in AD patients with CSF-biomarkers contradicts these findings [<xref rid='B18' ref-type='bibr'>18</xref>].</s><s sid='84'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Possible explanations for this discrepancy are the facts that the NPI subitem score for agitation was used to quantify agitation in that study, which is less sensitive as compared to CMAI, and that the study only included patients with mild AD not selected for BPSD.</s></p><p><s sid='85'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1>When all dementia subjects were included, there were no significant correlations between agitation and CSF biomarkers.</s><s sid='86'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> This suggests that the association of agitation with the burden of NFTs is restricted to AD patients only and not valid in the general dementia population.</s><s sid='87'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> No significant correlation was found between agitation and Aβ<sub>1-42</sub> in the AD group.</s><s sid='88'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Other studies have also failed to find an association between agitation and Aβ<sub>1-42</sub>[<xref rid='B18' ref-type='bibr'>18</xref>].</s><s sid='89'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Hyp1' type='Hyp'></CoreSc1> Although our result contradicts findings from a previous report that found a negative correlation between aggressive behavior and Aβ<sub>1-42</sub>[<xref rid='B20' ref-type='bibr'>20</xref>], the current study did not include adjustment for severity of dementia, which might have contributed to this association.</s><s sid='90'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Hyp1' type='Hyp'></CoreSc1> Since amyloid plaques are such an integral phenomenon of the pathophysiological process of AD, it is reasonable to believe that they are at least partially involved in the mechanism causing agitation.</s><s sid='91'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Hyp1' type='Hyp'></CoreSc1> A possible explanation for the lack of association between agitation and Aβ<sub>1-42</sub> could be that amyloid depositions are an upstream process to agitation, eventually leading to the presence of BPSD symptoms through mechanisms such as neuronal dysfunction or altered neurotransmission.</s><s sid='92'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> This theory is supported by the recent study finding that abnormal levels of AD biomarkers, including Aβ<sub>1-42</sub> and displaying a pattern of preclinical AD in healthy individuals, predicts an increased presence of BPSD in the future [<xref rid='B33' ref-type='bibr'>33</xref>].</s></p><p><s sid='93'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>Several limitations of this study have to be taken into account.</s><s sid='94'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> BPSD tend to fluctuate over time [<xref rid='B34' ref-type='bibr'>34</xref>].</s><s sid='95'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The association between agitation and dementia biomarkers may therefore change over time, and thus longitudinal studies may better capture this association.</s><s sid='96'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Some patients were also treated with stable psychotropic medications, and this may have influenced our findings.</s><s sid='97'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> In addition, the participants were selected from referrals to a university hospital and might thus have been biased.</s></p><p><s sid='98'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>In conclusion, our study provides added understanding of the pathological mechanism of BPSD in patients with dementia and suggests that tau-mediated pathology is associated with agitation in AD.</s><s sid='99'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> Further exploration of the possible pathological mechanism mediated by NFT is of interest in order to pinpoint and clarify the exact pathology associated with BPSD and to provide a basis for the development of patient-tailored pharmacological and therapeutic intervention.</s></p></sec><sec id='sec1_5'><title>Disclosure Statement</title><p>The present study is an academically initiated study initially financed by an independent grant from Janssen Pharmaceuticals, Stockholm, Sweden. The company was represented in the trial steering committee with regard to the study design but was not involved in patient collection or analyses of scientific data. This work was also supported by grants from the Petrus and Augusta Hedlunds Foundation as well as the Demensförbundet and Loo and Hans Osterman Foundation for Medical Research, Karolinska Institutet. J.C. owns the copyright of the NPI.</p></sec></body><back><ack><title>Acknowledgements</title><p>We want to express our gratitude to the patients, caregivers and staff at the Outpatient Memory Clinic and Inpatient Wards at the Department of Geriatrics, Karolinska University Hospital Huddinge, Stockholm, Sweden.</p></ack><ref-list><title>References</title><ref id='B1'><label>1</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Ferri</surname><given-names>CP</given-names></name><name><surname>Prince</surname><given-names>M</given-names></name><name><surname>Brayne</surname><given-names>C</given-names></name><name><surname>Brodaty</surname><given-names>H</given-names></name><name><surname>Fratiglioni</surname><given-names>L</given-names></name><name><surname>Gagnuli</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Global prevalence of dementia: a Delphi consensus study</article-title><source>Lancet</source><year>2005</year><volume>366</volume><fpage>2112</fpage><lpage>2117</lpage><pub-id pub-id-type='pmid'>16360788</pub-id></element-citation></ref><ref id='B2'><label>2</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Ritchie</surname><given-names>K</given-names></name><name><surname>Lovestone</surname><given-names>S</given-names></name></person-group><article-title>The dementias</article-title><source>Lancet</source><year>2002</year><volume>360</volume><fpage>1759</fpage><lpage>1766</lpage><pub-id pub-id-type='pmid'>12480441</pub-id></element-citation></ref><ref id='B3'><label>3</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>McKeith</surname><given-names>I</given-names></name><name><surname>Cummings</surname><given-names>J</given-names></name></person-group><article-title>Behavioural changes and psychological symptoms in dementia disorders</article-title><source>Lancet Neurology</source><year>2005</year><volume>4</volume><fpage>735</fpage><lpage>742</lpage></element-citation></ref><ref id='B4'><label>4</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Ballard</surname><given-names>C</given-names></name><name><surname>Day</surname><given-names>S</given-names></name><name><surname>Sharp</surname><given-names>S</given-names></name><name><surname>Wing</surname><given-names>G</given-names></name><name><surname>Sorensen</surname><given-names>S</given-names></name></person-group><article-title>Neuropsychiatric symptoms in dementia: importance and treatment considerations</article-title><source>Int Rev Psychiatry</source><year>2008</year><volume>20</volume><fpage>396</fpage><lpage>404</lpage><pub-id pub-id-type='pmid'>18925489</pub-id></element-citation></ref><ref id='B5'><label>5</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Lyketsos</surname><given-names>CG</given-names></name><name><surname>Lopez</surname><given-names>O</given-names></name><name><surname>Jones</surname><given-names>B</given-names></name><name><surname>Fitzpatrick</surname><given-names>AL</given-names></name><name><surname>Breitner</surname><given-names>J</given-names></name><name><surname>DeKosky</surname><given-names>S</given-names></name></person-group><article-title>Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study</article-title><source>JAMA</source><year>2002</year><volume>288</volume><fpage>1475</fpage><lpage>1483</lpage><pub-id pub-id-type='pmid'>12243634</pub-id></element-citation></ref><ref id='B6'><label>6</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Ballard</surname><given-names>C</given-names></name><name><surname>Corbett</surname><given-names>A</given-names></name></person-group><article-title>Management of neuropsychiatric symptoms in people with dementia</article-title><source>CNS Drugs</source><year>2010</year><volume>24</volume><fpage>729</fpage><lpage>739</lpage><pub-id pub-id-type='pmid'>20806986</pub-id></element-citation></ref><ref id='B7'><label>7</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Grossberg</surname><given-names>GT</given-names></name></person-group><article-title>The ABC of Alzheimer's disease: behavioral symptoms and their treatment</article-title><source>Int Psychogeriatr</source><year>2002</year><volume>14</volume><fpage>27</fpage><lpage>49</lpage><pub-id pub-id-type='pmid'>12636179</pub-id></element-citation></ref><ref id='B8'><label>8</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Schnaider Beeri</surname><given-names>M</given-names></name><name><surname>Werner</surname><given-names>P</given-names></name><name><surname>Davidson</surname><given-names>M</given-names></name><name><surname>Noy</surname><given-names>S</given-names></name></person-group><article-title>The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer's disease patients</article-title><source>Int J Geriatr Psychiatry</source><year>2002</year><volume>17</volume><fpage>403</fpage><lpage>408</lpage><pub-id pub-id-type='pmid'>11994927</pub-id></element-citation></ref><ref id='B9'><label>9</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Cerejeira</surname><given-names>J</given-names></name><name><surname>Lagarto</surname><given-names>L</given-names></name><name><surname>Mukaetova-Ladinska</surname><given-names>EB</given-names></name></person-group><article-title>Behavioral and psychological symptoms of dementia</article-title><source>Front Neurol</source><year>2012</year><volume>3</volume><fpage>73</fpage><pub-id pub-id-type='pmid'>22586419</pub-id></element-citation></ref><ref id='B10'><label>10</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Allegri</surname><given-names>RF</given-names></name><name><surname>Sarasola</surname><given-names>D</given-names></name><name><surname>Serrano</surname><given-names>CM</given-names></name><name><surname>Taragano</surname><given-names>FE</given-names></name><name><surname>Arizaga</surname><given-names>RL</given-names></name><name><surname>Butman</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Neuropsychiatric symptoms as a predictor of caregiver burden in Alzheimer's disease</article-title><source>Neuropsychiatr Dis Treat</source><year>2006</year><volume>2</volume><fpage>105</fpage><lpage>110</lpage><pub-id pub-id-type='pmid'>19412452</pub-id></element-citation></ref><ref id='B11'><label>11</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Pugh</surname><given-names>PL</given-names></name><name><surname>Richardson</surname><given-names>JC</given-names></name><name><surname>Bate</surname><given-names>ST</given-names></name><name><surname>Upton</surname><given-names>N</given-names></name><name><surname>Sunter</surname><given-names>D</given-names></name></person-group><article-title>Non-cognitive behaviours in an APP/PS1 transgenic model of Alzheimer's disease</article-title><source>Behav Brain Res</source><year>2007</year><volume>178</volume><fpage>18</fpage><lpage>28</lpage><pub-id pub-id-type='pmid'>17229472</pub-id></element-citation></ref><ref id='B12'><label>12</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Tekin</surname><given-names>S</given-names></name><name><surname>Mega</surname><given-names>MS</given-names></name><name><surname>Masterman</surname><given-names>DM</given-names></name><name><surname>Chow</surname><given-names>T</given-names></name><name><surname>Garakian</surname><given-names>J</given-names></name><name><surname>Vinter</surname><given-names>HV</given-names></name><etal></etal></person-group><article-title>Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease</article-title><source>Ann Neurol</source><year>2001</year><volume>49</volume><fpage>355</fpage><lpage>361</lpage><pub-id pub-id-type='pmid'>11261510</pub-id></element-citation></ref><ref id='B13'><label>13</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Matthews</surname><given-names>KL</given-names></name><name><surname>Chen</surname><given-names>CPL</given-names></name><name><surname>Esiri</surname><given-names>MM</given-names></name><name><surname>Keene</surname><given-names>J</given-names></name><name><surname>Minger</surname><given-names>SL</given-names></name><name><surname>Francis</surname><given-names>PT</given-names></name></person-group><article-title>Noradrenergic changes, aggressive behavior, and cognition in patients with dementia</article-title><source>Biol Psychiatry</source><year>2002</year><volume>51</volume><fpage>407</fpage><lpage>416</lpage><pub-id pub-id-type='pmid'>11904135</pub-id></element-citation></ref><ref id='B14'><label>14</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Lanari</surname><given-names>A</given-names></name><name><surname>Amenta</surname><given-names>F</given-names></name><name><surname>Silvestrelli</surname><given-names>G</given-names></name><name><surname>Tomassoni</surname><given-names>D</given-names></name><name><surname>Pernetti</surname><given-names>L</given-names></name></person-group><article-title>Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer's disease</article-title><source>Mech Ageing Dev</source><year>2006</year><volume>127</volume><fpage>158</fpage><lpage>165</lpage><pub-id pub-id-type='pmid'>16297434</pub-id></element-citation></ref><ref id='B15'><label>15</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Hampel</surname><given-names>H</given-names></name><name><surname>Weiner</surname><given-names>M</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name></person-group><article-title>Cerebrospinal fluid and plasma biomarkers in Alzheimer's Disease</article-title><source>Nat Rev Neurol</source><year>2010</year><volume>6</volume><fpage>131</fpage><lpage>144</lpage><pub-id pub-id-type='pmid'>20157306</pub-id></element-citation></ref><ref id='B16'><label>16</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Prvulovic</surname><given-names>D</given-names></name><name><surname>Hampel</surname><given-names>H</given-names></name></person-group><article-title>Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease</article-title><source>Clin Chem Lab Med</source><year>2011</year><volume>49</volume><fpage>367</fpage><lpage>374</lpage><pub-id pub-id-type='pmid'>21342022</pub-id></element-citation></ref><ref id='B17'><label>17</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Spies</surname><given-names>PE</given-names></name><name><surname>Claassen</surname><given-names>JAHR</given-names></name><name><surname>Peer</surname><given-names>PGM</given-names></name><name><surname>Blankenstein</surname><given-names>MA</given-names></name><name><surname>Teunissen</surname><given-names>CE</given-names></name><name><surname>Scheltens</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>A prediction model to calculate probability of Alzheimer's disease using cerebrospinal fluid biomarkers</article-title><source>Alzheimers Dement</source><year>2013</year><volume>9</volume><fpage>262</fpage><lpage>268</lpage><pub-id pub-id-type='pmid'>23123231</pub-id></element-citation></ref><ref id='B18'><label>18</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Skogseth</surname><given-names>R</given-names></name><name><surname>Mulugeta</surname><given-names>E</given-names></name><name><surname>Ballard</surname><given-names>C</given-names></name><name><surname>Rongve</surname><given-names>A</given-names></name><name><surname>Nore</surname><given-names>S</given-names></name><name><surname>Alves</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Neuropsychiatric correlates of cerebrospinal fluid biomarkers in Alzheimer's disease</article-title><source>Dement Geriatr Cogn Disord</source><year>2008</year><volume>25</volume><fpage>559</fpage><lpage>563</lpage><pub-id pub-id-type='pmid'>18536520</pub-id></element-citation></ref><ref id='B19'><label>19</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Kramberger</surname><given-names>MG</given-names></name><name><surname>Jelic</surname><given-names>V</given-names></name><name><surname>Kåreholt</surname><given-names>I</given-names></name><name><surname>Enache</surname><given-names>D</given-names></name><name><surname>Eriksdotter Jönhagen</surname><given-names>M</given-names></name><name><surname>Winblad</surname><given-names>B</given-names></name><etal></etal></person-group><article-title>CSF Alzheimer-markers in depressed elderly with and without Alzheimer's disease</article-title><source>Dement Geriatr Cogn Dis Extra</source><year>2012</year><volume>2</volume><fpage>48</fpage><lpage>56</lpage><pub-id pub-id-type='pmid'>22649429</pub-id></element-citation></ref><ref id='B20'><label>20</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Engelborghs</surname><given-names>S</given-names></name><name><surname>Maertens</surname><given-names>K</given-names></name><name><surname>Vloeberghs</surname><given-names>E</given-names></name><name><surname>Aerts</surname><given-names>T</given-names></name><name><surname>Somers</surname><given-names>N</given-names></name><name><surname>Marien</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Neuropsychological and behavioural correlates of CSF biomarkers in dementia</article-title><source>Neurochem Int</source><year>2006</year><volume>48</volume><fpage>286</fpage><lpage>295</lpage><pub-id pub-id-type='pmid'>16434124</pub-id></element-citation></ref><ref id='B21'><label>21</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Sink</surname><given-names>KM</given-names></name><name><surname>Holden</surname><given-names>KF</given-names></name><name><surname>Yaffe</surname><given-names>K</given-names></name></person-group><article-title>Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence</article-title><source>JAMA</source><year>2005</year><volume>293</volume><fpage>596</fpage><lpage>608</lpage><pub-id pub-id-type='pmid'>15687315</pub-id></element-citation></ref><ref id='B22'><label>22</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Freund-Levi</surname><given-names>Y</given-names></name><name><surname>Bloniecki</surname><given-names>V</given-names></name><name><surname>Auestad</surname><given-names>B</given-names></name><name><surname>Tysen Bäckström</surname><given-names>A</given-names></name><name><surname>Lärksäter</surname><given-names>M</given-names></name><name><surname>Aarsland</surname><given-names>D</given-names></name></person-group><article-title>Galantamine versus risperidone for agitation in people with dementia: a randomized, twelve-week, single-center study</article-title><source>Dement Geriatr Cogn Disord</source><year>2014</year><volume>38</volume><fpage>234</fpage><lpage>244</lpage><pub-id pub-id-type='pmid'>24969380</pub-id></element-citation></ref><ref id='B23'><label>23</label><element-citation publication-type='book'><collab>American Psychiatric Association</collab><source>Diagnostic and Statistical Manual of Mental Disorders</source><year>1995</year><edition>ed 4</edition><publisher-loc>Washington</publisher-loc><publisher-name>American Psychiatric Association</publisher-name></element-citation></ref><ref id='B24'><label>24</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Cummings</surname><given-names>JL</given-names></name><name><surname>Mega</surname><given-names>M</given-names></name><name><surname>Gray</surname><given-names>K</given-names></name><name><surname>Rosenberg-Thompson</surname><given-names>S</given-names></name><name><surname>Carusi</surname><given-names>DA</given-names></name><name><surname>Gornbein</surname><given-names>J</given-names></name></person-group><article-title>The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia</article-title><source>Neurology</source><year>1994</year><volume>44</volume><fpage>2308</fpage><lpage>2314</lpage><pub-id pub-id-type='pmid'>7991117</pub-id></element-citation></ref><ref id='B25'><label>25</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Freund-Levi</surname><given-names>Y</given-names></name><name><surname>Jedenius</surname><given-names>E</given-names></name><name><surname>Tysen-Bäckström</surname><given-names>AN</given-names></name><name><surname>Lärksäter</surname><given-names>M</given-names></name><name><surname>Wahlund</surname><given-names>LO</given-names></name><name><surname>Eriksdotter</surname><given-names>M</given-names></name></person-group><article-title>Galantamine versus risperidone treatment of neuropsychiatric symptoms in patients with probable dementia: an open randomised trial</article-title><source>Am J Geriatr Psychiatry</source><year>2014</year><volume>22</volume><fpage>341</fpage><lpage>348</lpage><pub-id pub-id-type='pmid'>24035407</pub-id></element-citation></ref><ref id='B26'><label>26</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Folstein</surname><given-names>MF</given-names></name><name><surname>Folstein</surname><given-names>SE</given-names></name><name><surname>McHugh</surname><given-names>PR</given-names></name></person-group><article-title>‘Mini-mental state’</article-title><source>A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res</source><year>1975</year><volume>12</volume><fpage>189</fpage><lpage>198</lpage></element-citation></ref><ref id='B27'><label>27</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Cohen-Mansfield</surname><given-names>J</given-names></name><name><surname>Billig</surname><given-names>N</given-names></name></person-group><article-title>Agitated behaviors in the elderly</article-title><source>I – A Conceptual review. J Am Geriatr Soc</source><year>1986</year><volume>34</volume><fpage>711</fpage><lpage>721</lpage></element-citation></ref><ref id='B28'><label>28</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Wallin</surname><given-names>A</given-names></name><name><surname>Agren</surname><given-names>H</given-names></name><name><surname>Spenger</surname><given-names>C</given-names></name><name><surname>Siegfried</surname><given-names>J</given-names></name><name><surname>Vanmechelen</surname><given-names>E</given-names></name></person-group><article-title>Tau protein in cerebrospinal fluid: a biochemical diagnostic marker for axonal degeneration in Alzheimer's disease?</article-title><source>Mol Chem Neuropathology</source><year>1995</year><volume>26</volume><fpage>231</fpage><lpage>245</lpage></element-citation></ref><ref id='B29'><label>29</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Vanmechelen</surname><given-names>E</given-names></name><name><surname>Vanderstichele</surname><given-names>H</given-names></name><name><surname>Davidsson</surname><given-names>P</given-names></name><name><surname>Van Kerschaver</surname><given-names>E</given-names></name><name><surname>Van Der Perre</surname><given-names>B</given-names></name><name><surname>Sjögren</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization</article-title><source>Neurosci Lett</source><year>2000</year><volume>285</volume><fpage>49</fpage><lpage>52</lpage><pub-id pub-id-type='pmid'>10788705</pub-id></element-citation></ref><ref id='B30'><label>30</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Andreasen</surname><given-names>N</given-names></name><name><surname>Hesse</surname><given-names>C</given-names></name><name><surname>Davidsson</surname><given-names>P</given-names></name><name><surname>Minthon</surname><given-names>L</given-names></name><name><surname>Wallin</surname><given-names>A</given-names></name><name><surname>Winblad</surname><given-names>B</given-names></name><etal></etal></person-group><article-title>Cerebrospinal fluid B-amyloid<sub>(1-42)</sub> in Alzheimer's disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease</article-title><source>Arch Neurol</source><year>1999</year><volume>56</volume><fpage>673</fpage><lpage>680</lpage><pub-id pub-id-type='pmid'>10369305</pub-id></element-citation></ref><ref id='B31'><label>31</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name></person-group><article-title>Cerebrospinal fluid biomarkers for Alzheimer's disease</article-title><source>J Alzheimers Dis</source><year>2009</year><volume>18</volume><fpage>413</fpage><lpage>417</lpage><pub-id pub-id-type='pmid'>19661632</pub-id></element-citation></ref><ref id='B32'><label>32</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Senanarong</surname><given-names>V</given-names></name><name><surname>Cummings</surname><given-names>JL</given-names></name><name><surname>Fairbanks</surname><given-names>L</given-names></name><name><surname>Mega</surname><given-names>M</given-names></name><name><surname>Masterman</surname><given-names>DM</given-names></name><name><surname>O'Connor</surname><given-names>SM</given-names></name><name><surname>Strickland</surname><given-names>TL</given-names></name></person-group><article-title>Agitation in Alzheimer's disease is a manifestation of frontal lobe dysfunction</article-title><source>Dement Geriatr Cogn Disord</source><year>2004</year><volume>17</volume><fpage>14</fpage><lpage>20</lpage><pub-id pub-id-type='pmid'>14560060</pub-id></element-citation></ref><ref id='B33'><label>33</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Roe</surname><given-names>CM</given-names></name><name><surname>Fagan</surname><given-names>AM</given-names></name><name><surname>Grant</surname><given-names>EA</given-names></name><name><surname>Holtzman</surname><given-names>DM</given-names></name><name><surname>Morris</surname><given-names>JC</given-names></name></person-group><article-title>CSF biomarkers of Alzheimer disease: ‘noncognitive’ outcomes</article-title><source>Neurology</source><year>2013</year><volume>81</volume><fpage>2028</fpage><lpage>2031</lpage><pub-id pub-id-type='pmid'>24212387</pub-id></element-citation></ref><ref id='B34'><label>34</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Lawlor</surname><given-names>B</given-names></name></person-group><article-title>Managing behavioural and psychological symptoms in dementia</article-title><source>B J Psychiatry</source><year>2002</year><volume>181</volume><fpage>463</fpage><lpage>465</lpage></element-citation></ref></ref-list></back><floats-group><fig orientation='portrait' id='F1' position='float'><label>Fig. 1</label><caption><p>Scatterplots of Spearman's correlations between dementia biomarkers in CSF and total CMAI. <bold>a</bold> Scatterplot of the correlation between T-tau and total CMAI in AD patients. <bold>b</bold> Scatterplot of the correlation between P-tau and total CMAI in AD patients. <bold>c</bold> Scatterplot of the correlation between P-tau and total CMAI in all patients. <bold>d</bold> Scatterplot of the correlation between T-tau and total CMAI in all patients. <bold>e</bold> Scatterplot of the correlation between Aβ<sub>1-42</sub> and total CMAI in AD patients.</p></caption><graphic xlink:href='dee-0004-0335-g01'></graphic></fig><table-wrap orientation='portrait' id='T1' position='float'><label>Table 1</label><caption><p>Baseline characteristics of the included patients</p></caption><table rules='groups' frame='hsides'><thead><tr><th colspan='1' rowspan='1' align='left'>Variables</th><th colspan='1' rowspan='1' align='left'>All (n = 95)</th><th colspan='1' rowspan='1' align='left'>AD (n = 33)</th></tr></thead><tbody><tr><td colspan='1' rowspan='1' align='left'>Age, years</td><td colspan='1' rowspan='1' align='left'>78.6 ± 7.5</td><td colspan='1' rowspan='1' align='left'>78.7 ± 7.6</td></tr><tr><td colspan='1' rowspan='1' align='left'>Females, n</td><td colspan='1' rowspan='1' align='left'>63</td><td colspan='1' rowspan='1' align='left'>19</td></tr><tr><td colspan='1' rowspan='1' align='left'>MMSE (0 – 30 points)</td><td colspan='1' rowspan='1' align='left'>20.2 ± 4.6</td><td colspan='1' rowspan='1' align='left'>19.1 ± 4.2</td></tr><tr><td colspan='1' rowspan='1' align='left'>Total CMAI (0 – 203 points)</td><td colspan='1' rowspan='1' align='left'>46.3 ± 11.8</td><td colspan='1' rowspan='1' align='left'>44.6 ± 10.7</td></tr><tr><td colspan='1' rowspan='1' align='left'>CMAI aggressive physical behavior (0 – 77 points)</td><td colspan='1' rowspan='1' align='left'>11.6 ± 2.0</td><td colspan='1' rowspan='1' align='left'>11.6 ± 2.6</td></tr><tr><td colspan='1' rowspan='1' align='left'>CMAI nonaggressive physical behavior (0 – 70 points)</td><td colspan='1' rowspan='1' align='left'>17.3 ± 6.6</td><td colspan='1' rowspan='1' align='left'>17.3 ± 6.1</td></tr><tr><td colspan='1' rowspan='1' align='left'>CMAI verbal aggressive behavior (0 – 21 points)</td><td colspan='1' rowspan='1' align='left'>4.9 ± 2.3</td><td colspan='1' rowspan='1' align='left'>4.5 ± 1.9</td></tr><tr><td colspan='1' rowspan='1' align='left'>CMAI verbal nonaggressive behavior (0 – 35 points)</td><td colspan='1' rowspan='1' align='left'>12.5 ± 5.7</td><td colspan='1' rowspan='1' align='left'>11.2 ± 5.3</td></tr><tr><td colspan='1' rowspan='1' align='left'>T-tau, pg/ml</td><td colspan='1' rowspan='1' align='left'>775.4 ± 527.6</td><td colspan='1' rowspan='1' align='left'>767.6 ± 472.9</td></tr><tr><td colspan='1' rowspan='1' align='left'>P-tau, pg/ml</td><td colspan='1' rowspan='1' align='left'>97.4 ± 58.1</td><td colspan='1' rowspan='1' align='left'>94.8 ± 44.9</td></tr><tr><td colspan='1' rowspan='1' align='left'>Aβ<sub>1</sub><sub>− 42</sub>, pg/ml</td><td colspan='1' rowspan='1' align='left'>478.2 ± 182.4</td><td colspan='1' rowspan='1' align='left'>464.4 ± 141.0</td></tr></tbody></table><table-wrap-foot><fn><p>All values are expressed as means ± SD, except for the number of females.</p></fn></table-wrap-foot></table-wrap><table-wrap orientation='portrait' id='T2' position='float'><label>Table 2</label><caption><p>Correlations between agitation and dementia biomarkers in CSF</p></caption><table rules='groups' frame='hsides'><thead><tr><th colspan='1' rowspan='1' align='left'>Variables</th><th colspan='1' rowspan='1' align='left'>All (n = 95)</th><th colspan='1' rowspan='1' align='left'>AD (n = 33)</th></tr></thead><tbody><tr><td colspan='1' rowspan='1' align='left'>Total CMAI and T-tau</td><td colspan='1' rowspan='1' align='left'>0.13 (p = 0.2)</td><td colspan='1' rowspan='1' align='left'>0.36 (p = 0.04)</td></tr><tr><td colspan='1' rowspan='1' align='left'>Total CMAI and Aβ<sub>1 – 42</sub></td><td colspan='1' rowspan='1' align='left'>0.04 (p = 0.7)</td><td colspan='1' rowspan='1' align='left'>−0.11 (p = 0.6)</td></tr><tr><td colspan='1' rowspan='1' align='left'>Total CMAI and P-tau</td><td colspan='1' rowspan='1' align='left'>0.12 (p = 0.3)</td><td colspan='1' rowspan='1' align='left'>0.35 (p = 0.05)</td></tr></tbody></table><table-wrap-foot><fn><p>Spearman's correlation was used for statistical calculations.</p></fn></table-wrap-foot></table-wrap></floats-group></article></PAPER>